Volume 22, Issue 1 (Iranian South Medical Journal 2019)
Iran South Med J 2019, 22(1): 62-76 |
Back to browse issues page
1- Department of Biochemistry, School of Medical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
2- Department of Anatomical Sciences, School of Medical Sciences, Bushehr University of Medical Sciences, Bushehr, Iran
3- Department of Biochemistry, School of Medical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran , shafieem@sums.ac.ir
2- Department of Anatomical Sciences, School of Medical Sciences, Bushehr University of Medical Sciences, Bushehr, Iran
3- Department of Biochemistry, School of Medical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran , shafieem@sums.ac.ir
Abstract: (5120 Views)
Background: Osteoporosis is a prevalent bone disease caused by an imbalance between bone formation and resorption. Nutritional factors are involved in the prevention of osteoporosis. Several treatments exist for osteoporosis including bisphosphonates, parathyroid hormone, estrogen therapy, and hormone therapy, which have their own side effects. In the quest for an appropriate treatment for osteoporosis, researchers are now turning toward the nature-based medications such as marine algae (seaweed). The aim of the present review is to investigate the effects of algae on osteoporosis.
Materials and Methods: We examined articles indexed in PubMed, Science Direct and Google Scholar databases. It should be noted that human studies on the beneficial effects of seaweed on osteoporosis are rare.
Results: Seaweeds have several health benefits including their effect on bone metabolism. Active ingredients of algae have anti-cancer, anti-inflammatory, and antioxidant properties in addition to other features that heal various diseases. Research has shown that algae improve bone metabolism because they are a rich source of essential minerals such as calcium, magnesium, other bone-supporting elements, amino acids and growth factors.
Conclusion: The extracted compounds from algae are biocompatible, and do not have the side effects of synthetic medications; therefore, they can be used for osteoporosis treatment.
Materials and Methods: We examined articles indexed in PubMed, Science Direct and Google Scholar databases. It should be noted that human studies on the beneficial effects of seaweed on osteoporosis are rare.
Results: Seaweeds have several health benefits including their effect on bone metabolism. Active ingredients of algae have anti-cancer, anti-inflammatory, and antioxidant properties in addition to other features that heal various diseases. Research has shown that algae improve bone metabolism because they are a rich source of essential minerals such as calcium, magnesium, other bone-supporting elements, amino acids and growth factors.
Conclusion: The extracted compounds from algae are biocompatible, and do not have the side effects of synthetic medications; therefore, they can be used for osteoporosis treatment.
Type of Study: Original |
Subject:
Endocrine System
Received: 2017/12/12 | Accepted: 2018/10/3 | Published: 2019/04/7
Received: 2017/12/12 | Accepted: 2018/10/3 | Published: 2019/04/7
References
1. Mironidou-Tzouveleki Μ, Dokos CH, Dokou K. Effects of Extracts of Marine Algae on Osteoporosis. Aristotle Univ Med J 2008; 35: 7-12.
2. Nguyen MH, Jung WK, Kim SK. Marine Algae Possess Therapeutic Potential for Camineralization via Osteoblastic Differentiation. Adv Food Nutr Res 2011; 64: 429-41. [DOI:10.1016/B978-0-12-387669-0.00033-8]
3. Venkatesan J, Kim SK. Osteoporosis Treatment: Marine Algal Compounds. Adv Food Nutr Res 2011; 64: 417-27. [DOI:10.1016/B978-0-12-387669-0.00032-6]
4. Francavilla M, Franchi M, Monteleone M, et al. The Red Seaweed Gracilaria Gracilis as a Multi Products Source. Mar drugs 2013; 11(10): 3754-76. [DOI:10.3390/md11103754]
5. Rodrigues D, Freitas AC, Pereira L, et al. Chemical Composition of Red, Brown and Green Macroalgae from Buarcos Vay in Central West Coast of Portugal. Food Chem 2015; 183: 197-207. [DOI:10.1016/j.foodchem.2015.03.057]
6. Taichman RS. Blood and Bone: Two Tissues Whose Fates Are Intertwined to Create the Hematopoietic Stem Cell Niche. Blood 2005; 105(7): 2631-9. [DOI:10.1182/blood-2004-06-2480]
7. Gay CV, Gilman VR, Sugiyama T. Perspectives on Osteoblast and Osteoclast Function. Poult Sci 2000; 79(7): 1005-8. [DOI:10.1093/ps/79.7.1005]
8. Logan CY, Nusse R. The Wnt Signaling Pathway in Development and Disease. Annu Rev Cell Dev Biol 2004; 20: 781-810. [DOI:10.1146/annurev.cellbio.20.010403.113126]
9. Boulpaep EL, Boron WF, Caplan MJ, et al. Medical Physiology: A Cellular and Molecular Approach. First ed. Philadelphia, PA: Saunders, 2005, 1089-91.
10. Harada S, Rodan GA. Control of Osteoblast Function and Regulation of Bone Mass. Nature 2003; 423(6937): 349-55. [DOI:10.1038/nature01660]
11. Miyamoto T, Suda T. Differentiation and Function of Osteoclasts. Keio J Med 2003; 52(1): 1-7. Keio J Med 2003; 52(1): 1-7. [DOI:10.2302/kjm.52.1]
12. Constantz BR, Ison IC, Fulmer MT, et al. Skeletal Repair by in Situ Formation of the Mineral Phase of Bone. Science 1995; 267(5205): 1796-9. [DOI:10.1126/science.7892603]
13. Zamurovic N, Cappellen D, Rohner D, et al. Coordinated Activation of Notch, Wnt, and Transforming Growth Factor-beta Signaling Pathways in Bone Morphogenic Protein 2-induced Osteogenesis. Notch Target Gene Hey1 Inhibits Mineralization and Runx2 Transcriptional Activity. J Biol Chem 2004; 279(36): 37704-15. [DOI:10.1074/jbc.M403813200]
14. Dimitriou R, Tsiridis E, Giannoudis PV. Current Concepts of Molecular Aspects of Bone Healing. Injury 2005; 36(12): 1392-404. [DOI:10.1016/j.injury.2005.07.019]
15. Pelissier P, Masquelet AC, Bareille R, et al. Induced Membranes Secrete Growth Factors Including Vascular and Osteoinductive Factors and Could Stimulate Bone Regeneration. J Orthop Res 2004; 22(1): 73-9. [DOI:10.1016/S0736-0266(03)00165-7]
16. Zhang F, Xu L, Xu L, et al. Histone Demethylase JMJD3 is Required for Osteoblast Differentiation in Mice. Sci Rep 2015; 5: 13418. [DOI:10.1038/srep13418]
17. Ye L, Fan Z, Yu B, et al. Histone Demethylases KDM4B and KDM6B Promotes Osteogenic Differentiation of Human MSCs. Cell Stem Cell 2012; 11(1): 50-61. [DOI:10.1016/j.stem.2012.04.009]
18. Koch H, Jadlowiec JA, Campbell PG. Insulin-like growth Factor-I Induces Early Osteoblast Gene Expression in Human Mesenchymal Stem Cells. Stem Cells Dev 2005; 14(6): 621-31. [DOI:10.1089/scd.2005.14.621]
19. Crane JL, Zhao L, Frye JS, et al. IGF-1 signaling is Essential for Differentiation of Mesenchymal Stem Cells for Peak Bone Mass. Bone Res 2013; 1(2): 186-94. [DOI:10.4248/BR201302007]
20. Xian L, Wu X, Pang L, et al. Matrix IGF-1 Maintains Bone Mass by Activation of mTOR in Mesenchymal Stem Cells. Nat Med 2012; 18(7):1095-10. [DOI:10.1038/nm.2793]
21. Wei Y, Chen YH, Li LY, et al. CDK1- dependent Phosphorylation of EZH2 Suppresses Methylation of H3K27 and Promotes Osteogenic Differentiation of Human Mesenchymal Stem Cells. Nat Cell Biol 2011; 13(1): 87-94. [DOI:10.1038/ncb2139]
22. Cho YS, Jung WK, Kim Ja, et al. Beneficial Effects of Fucoidan on Osteoblastic MG-63 Cell Differentiation. Food Chem 2009; 116(4): 990-4. [DOI:10.1016/j.foodchem.2009.03.051]
23. Kim BS, Kang HJ, Park JY, et al. Fucoidan Promotes Osteoblast Differentiation via JNK- and ERK-dependent BMP2-Smad 1/5/8 Signaling in Human Mesenchymal Stem Cells. Exp Mol Med 2015; 47: e128. [DOI:10.1038/emm.2014.95]
24. Hosogane N, Huang Z, Rawlins BA, et al. Stromal Derived Factor-1 regulates Bone Morphogenetic Protein 2-induced Osteogenic Differentiation of primary Mesenchymal Stem Cells. Int J Biochem Cell Biol 2010; 42(7): 1132-41. [DOI:10.1016/j.biocel.2010.03.020]
25. Komori T. Regulation of Osteoblast Differentiation by Transcription Factors. J Cell Biochem 2006; 99(5): 1233-9. [DOI:10.1002/jcb.20958]
26. Ding J, Ghali O, Lencel P, et al. TNF-α and IL-1β inhibit RUNX2 and Collagen Expression but Increase Alkaline Phosphatase Activity and Mineralization in Human Mesenchymal Stem Cells. Life Sci 2009; 84(15-16): 499-504. [DOI:10.1016/j.lfs.2009.01.013]
27. Hong JH, Yaffe MB. TAZ: a β-catenin-like Molecule that Regulates Mesenchymal Stem Cell Differentiation. Cell Cycle 2006; 5: 176-9. [DOI:10.4161/cc.5.2.2362]
28. Aubin JE, Liu F, Malaval L, et al., Osteoblast and Chondroblast Differentiation. Bone 1995; 17(2 Suppl): 77S-83S [DOI:10.1016/8756-3282(95)00183-E]
29. Consensus A. Consensus Development Conference: Diagnosis, Prophylaxis, and Treatment of Osteoporosis. Am J Med 1993; 94(6): 646-50. [DOI:10.1016/0002-9343(93)90218-E]
30. Ray NF, Chan JK, Thamer M, et al. Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12(1): 24-35. [DOI:10.1359/jbmr.1997.12.1.24]
31. Lau EM. Osteoporosisea Worldwide Problem and the Implications in Asia. Ann Acad Med Singapore 2002; 31(1): 67-8.
32. Riggs BL, Melton LJ III. The Worldwide Problem of Osteoporosis: Insights Afforded by Epidemiology. Bone 1995; 17(5 Suppl): 505S-511S. [DOI:10.1016/8756-3282(95)00258-4]
33. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. report of a WHO study group. World Health Organ Tech Rep Ser 1994; 843: 1-129.
34. Kanis JA, Melton LJ III, Christiansen C, et al. The Diagnosis of Osteoporosis. J Bone Miner Res 1994; 9(8): 1137-41. [DOI:10.1002/jbmr.5650090802]
35. Kanis JA, Gluer CC. An Update on the Diagnosis and Assessment of Osteoporosis with Densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 2000; 11(3): 192-202. [DOI:10.1007/s001980050281]
36. Cooper C, Walker-Bone K, Arden N, et al. Novel Insights into the Pathogenesis of Osteoporosis: The Role of Intrauterine Programming. Rheumatology 2000; 39(12): 1312-15. [DOI:10.1093/rheumatology/39.12.1312]
37. Cooper C, Eriksson JG, Forson T, et al. Maternal Height, Childhood Growth and Risk of Hip Fracture in Later Life: A Longitudinal Study. Osteoporos Int 2001; 12(8): 623-9. [DOI:10.1007/s001980170061]
38. Larijani B, Moayyeri A, Keshtkar AA, et al. Peak Bone Mass of Iranian Population: The Iranian Multicenter Osteoporosis Study. J Clin Densitom 2006; 9(3): 367-74. [DOI:10.1016/j.jocd.2006.05.001]
39. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of Calcium and Vitamin D Supplementation on Bone Density in Men and Women 65 Years of Age or Older. N Engl J Med 1997; 337(10): 670-6. [DOI:10.1056/NEJM199709043371003]
40. Torpy JM, Lynm C, Glass RM. Osteopenia and Preventing Fractures. JAMA 2006; 296(21): 2644. [DOI:10.1001/jama.296.21.2644]
41. Eriksen EF. Treatment of Osteopenia. Rev Endocr Metab Disord 2012; 13(3): 209-23. [DOI:10.1007/s11154-011-9187-z]
42. Xiao Q, Murphy RA, Houston DK, et al. Dietary and Supplemental Calcium Intake and Cardiovascular Disease Mortality the National Institutes of Health-aarp Diet and Health. JAMA Intern Med 2013; 173(8): 639-46. [DOI:10.1001/jamainternmed.2013.3283]
43. Bolland MJ, Barber PA, Doughty RN, et al. Vascular Events in Healthy Older Women Receiving Calcium Supplementation: Randomised Controlled Trial. BMJ 2008; 336(7638): 262-6. [DOI:10.1136/bmj.39440.525752.BE]
44. Li K, Kaaks R, Linseisen J, et al. Associations of Dietary Calcium Intake and Calcium Supplementation with Myocardial Infarction and Stroke Risk and Overall Cardiovascular Mortality in the Heidelberg Cohort of the European Prospective Investigation into Cancer and Nutrition Study (epic-heidelberg). Heart 2012; 98(12): 920-5. [DOI:10.1136/heartjnl-2011-301345]
45. Stovall DW, Pinkerton JV. Estrogen Agonists/antagonists in Combination with Estrogen for Prevention and Treatment of Menopause-associated Signs and Symptoms. Womens Health (Lond) 2008; 4(3): 257-68. [DOI:10.2217/17455057.4.3.257]
46. Recker RR, Lewiecki EM, Miller PD. Safety of Bisphosphonates in the Treatment of Osteoporosis. Am J Med 2009; 122(2 Suppl): S22-32. [DOI:10.1016/j.amjmed.2008.12.004]
47. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates Promote Apoptosis in Murine Osteoclasts in Vitro and in Vivo. J Bone Miner Res 1995; 10(10): 1478-87. [DOI:10.1002/jbmr.5650101008]
48. Diel IJ, Bergner R, Grötz KA. Adverse Effects of Bisphosphonates. J Support Oncol 2007; 5(10): 475-82.
49. Dokos C, Myronidou-Tzouveleki M. SERMs: The Lovely Multi-Potential Drugs Targeting Osteoporosis?. Rev Clin Pharmacol Pharmacokinet-Int Ed 2007; 21(1): 75-82.
50. Kostoudi S, Koutousi C, Mironidou-Tzouveleki M. Osteoporosis: Treatment and Interactions. Epitheorese Klin Farmakol Farmakokinet 2003; 21(3):159-95.
51. Dokos Ch, Myronidou-Tzouveleki M. Pharmacological Properties of Phytoestrogens and Bone Health. Cyprus Med J 2007; 23(1-2): 9-11.
52. Mayer AM, Hamann MT. Marine Pharmacology in 1999: Compounds with Antibacterial, Anticoagulant, Antifungal, Anthelmintic, Anti-inflammatory, Antiplatelet, Antiprotozoal and Antiviral Activities Affecting the Cardiovascular, Endocrine, Immune and Nervous Systems, and other Miscellaneous Mechanisms of Action. Comp Biochem Physiol C 2002; 132(3): 315-39. [DOI:10.1016/S1532-0456(02)00094-7]
53. Mayer AM, Hamann MT. Marine Pharmacology in 2000: Marine Compounds with Antibacterial, Anticoagulant, Antifungal, Anti-inflammatory, Antimalarial, Antiplatelet, Antituberculosis, and Antiviral Activities; Affecting the Cardiovascular, Immune, and Nervous Systems and other Miscellaneous Mechanisms of Action. Mar Biotechnol Mar Biotechnol 2004; 6(1): 37-52. [DOI:10.1007/s10126-003-0007-7]
54. Mayer AM, Hamann MT. Marine Pharmacology in 2001-2002: Marine Compounds with Anthelmintic, Antibacterial, Anticoagulant, Antidiabetic, Antifungal, Anti-Inflammatory, Antimalarial, Antiplatelet, Antiprotozoal, Antituberculosis, and Antiviral Activities; Affecting the Cardiovascular, Immune and Nervous Systems and other Miscellaneous Mechanisms of action. Comp Biochem Physiol C Toxicol Pharmacol 2005; 140(3-4): 265-86. [DOI:10.1016/j.cca.2005.04.004]
55. Mayer AM, Rodríguez AD, Berlinck RG, et al. Marine Pharmacology in 2003-4: Marine Compounds With Anthelmintic Antibacterial, Anticoagulant, Antifungal, Anti-Inflammatory, Antimalarial, Antiplatelet, Antiprotozoal, Antituberculosis, and Antiviral Activitie; Affecting the Cardiovascular, Immune and Nervous Systems, and other Miscellaneous Mechanisms of Action. Comp Biochem Physiol C Toxicol Pharmacol 2007; 145(4): 553-81. [DOI:10.1016/j.cbpc.2007.01.015]
56. Mayer AM, Rodríguez AD, Berlinck RG, et al. Marine Pharmacology in 2005-6: Marine Compounds with Anthelmintic, Antibacterial, Anticoagulant, Antifungal, Anti-Inflammatory, Antimalarial, Antiprotozoal, Antituberculosis, and Antiviral Activities; Affecting the Cardiovascular, Immune and Nervous Systems, and other Miscellaneous Mechanisms of Action. Biochim Biophys Acta 2009; 1790(5): 283-308. [DOI:10.1016/j.bbagen.2009.03.011]
57. Mayer AM, Rodríguez AD, Berlinck RG, et al. Marine Pharmacology in 2007-8: Marine Compounds with Antibacterial, Anticoagulant, Antifungal, Anti-Inflammatory, Antimalarial, Antiprotozoal, Antituberculosis, and Antiviral Activities; Affecting the Immune and Nervous Systems, and other Miscellaneous Mechanisms of Action. Comp Biochem Physiol C Toxicol Pharmacol 2011; 153(2): 191-222. [DOI:10.1016/j.cbpc.2010.08.008]
58. Lauritano C, Andersen JH, Hansen E, et al. Bioactivity Screening of Microalgae for Antioxidant, Anti-Inflammatory, Anticancer, Anti-diabetes, and antibacterial activities. Front Mar Sci 2016; 3: 68. [DOI:10.3389/fmars.2016.00068]
59. Milledge J, Smith B, Dyer P, et al. Macroalgae-derived Biofuel: A Review of Methods of Energy Extraction from Seaweed Biomass. Energies 2014; 7(11): 7194-222. [DOI:10.3390/en7117194]
60. Suganya T, Varman M, Masjuki HH, et al. Macroalgae and Microalgae as a Potential Source for Commercial Applications Along with Biofuels Production: A Biorefinery Approach. Renew Sust Energ Rev 2016; 55: 909-41. [DOI:10.1016/j.rser.2015.11.026]
61. Sahayaraj, K. Biological Values and Conservation of Marine Algae: An Overview. In Proceedings of the Conservation and Sustainable Utilization of Marine Resources, National Conference on Conservation and Sustainable Utilization of Marine Resources, Tamil Nadu, India. 2015.
62. Plouguerné E, da Gama BA, Pereira RC, et al. Glycolipids from Seaweeds and their Potential Biotechnological Applications. Front Cell Infect Microbiol 2014; 4: 174. [DOI:10.3389/fcimb.2014.00174]
63. Dhargalkar VK, Pereira N. Seaweed: Promising Plant of the Millennium. Sci Cult 2005; 71: 60-6.
64. Ishimi Y, Sugiyama F, Ezaki Jet al. Effects of Spirulina, A Blue-green Alga, On Bone Me abolism in Ovariectomized Rats with Hindlimb-unloaded Mice. Biosci Biotechnol Biochem 2006; 70(2): 363-8. [DOI:10.1271/bbb.70.363]
65. Komai E, Miyahara T, Mori J, et al. Inhibitory Activities of Plastoquinones and Chromomene Derivative from Brown Alga Sargas°sum Micracanthum on Bone Resorption. Biol Pharm Bull 2006; 29(9): 1980-2. [DOI:10.1248/bpb.29.1980]
66. Zandi K, Tajbakhsh S, Nabipour I, et al. In Vitro Antitumor Activity of Gracilaria Corticata (a red alga) Against Jurkat and Molt-4 Human Cancer Cell Lines. Afr J Biotechnol 2010; 9(40): 6787-90.
67. Momeni S, Safavi A, Ahmadi R, et al. Gold Nanosheets Synthesized with Red Marine Alga Actinotrichia Fragilis as Efficient Electrocatalysts Toward Formic Acid Oxidation. RSC Adv 2016; 6(79): 75152-61. [DOI:10.1039/C6RA14691K]
68. Heidari M, Zolgharnine H, Sakhaei N, et al. Antibacterial and Anti-oxidant activity of three Species of green, Brown and Red Algae from Northern Coast of Persian Gulf. Iran South Med J 2015; 18(2): 383-92.
69. Galea R, Montalto AS, Brincat M, et al. Phytoestrogen/SERM like Activity from a marine Alga Derived Molecule on Bone Density and Collagen Markers in Postmenopausal Women. Int J Gynaecol Obstet 2000; 70(Suppl1): A31. [DOI:10.1016/S0020-7292(00)82056-1]
70. Uchiyama S, Yamaguchi M. Preventive Effect of Marine Alga Sargassum Horneri Extract on Bone Loss in Streptozoticin-diabetic Rats in Vivo. J Health Sci 2003; 49(2): 149-55. [DOI:10.1248/jhs.49.149]
71. Michalek JE, Preuss HG, Croft HA, et al. Changes in Total Body Bone Mineral Density Following a Common Bone Health Plan with Two Versions of a Unique Bone Health Supplement: A Comparative Effectiveness Research Study. Nutr J 2011; 10(1): 32. [DOI:10.1186/1475-2891-10-32]
72. Round, FE. The Biology of the Algae. 2nd ed. Edward Arnold Publishers: London, 1973, 201-5.
73. Adluri RS, Zhan L, Bagchi M, et al . Comparative Effects of a Novel Plant-based Calcium Supplement with Two Common Calcium Salts on Proliferation and Mineralization in Human Osteoblast Cells. Mol Cell Biochem 2010; 340(1-2): 73-80. [DOI:10.1007/s11010-010-0402-0]
74. Marone PA, Yasmin T, Gupta RC, et al. Safety and Toxicological Evaluation of AlgaeCal (AC), A Novel Plant-based Calcium Supplement. Toxicol Mech Methods 2010; 20(6): 334-44. [DOI:10.3109/15376516.2010.490966]
75. Aslam MN, Kreider JM, Paruchuri T, et al. A Mineral-rich Extract from the red Marine Algae Lithothamnion Calcareum Preserves Bone Structure and Function in Female Mice on a Western-Style Diet. Calcif Tissue Int 2010; 86(4): 313-24. [DOI:10.1007/s00223-010-9340-9]
76. O'gorman DM, Tierney CM, Brennan O, et al. The Marine‐derived, Multi‐mineral Formula, Aquamin, Enhances Mineralisation of Osteoblast Cells in Vitro. Phytother Res 2012; 26(3): 375-80. [DOI:10.1002/ptr.3561]
77. Uchiyama S, Hashizume M, Hokari Y, et al. Characterization of Active Component in Marine Alga Sargassum Horneri Extract in Stimulating Bone Calcification in Vitro. J Health Sci 2004; 50(6): 634-9. [DOI:10.1248/jhs.50.634]
78. Yamaguchi M. Regulatory Mechanism of Food Factors in Bone Metabolism and Prevention of Osteoporosis. Yakugaku Zasshi 2006; 126(11): 1117-37. [DOI:10.1248/yakushi.126.1117]
79. Uchiyama S, Yamaguchi M. Anabolic Effect of Marine Alga Sargassum Horneri Extract on Bone Components in the Femoral-diaphyseal and -Metaphyseal Tissues of Young and Aged Rats in Vivo. J Health Sci 2002; 48(4): 325-30. [DOI:10.1248/jhs.48.325]
80. Ahn BN, Karadeniz F, Kong CS, et al. Dioxinodehydroeckol Enhances the Differentiation of Osteoblasts by Regulating the Expression of Phospho-Smad1/5/8. Mar Drugs 2016; 14(9): 168. [DOI:10.3390/md14090168]
81. Karadeniz F, Ahn BN, Kim JA, et al. Phlorotannins Suppress Adipogenesis in Pre-adipocytes while Enhancing Osteoblastogenesis in Pre-osteoblasts. Arch Pharm Res 2015; 38(12): 2172-82. [DOI:10.1007/s12272-015-0637-0]
82. Wang L, Wang H, Fang N. Algal Oligosaccharides Ameliorate Osteoporosis via Up-regulation of Parathyroid Hormone 1-84 and Vascular Endothelial Growth Factor. J Tradit Chin Med 2016; 36(3): 332-9. [DOI:10.1016/S0254-6272(16)30046-2]
83. Deng R, Zhou B, Guan B, et al. Marine Algae Extract Attenuated Osteoporosis in OVX Mice, Enhanced Osteogenesis on Human Mesenchymal Stem Cells and Promoted OPG Expression. J Funct Foods 2018; 40: 229-37. [DOI:10.1016/j.jff.2017.10.044]
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |